| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
VHL
|
|---|---|
| ln Vitro |
PROTAC EED degrader-2 (compound PROTAC 1) has a pKD of 9.27±0.05 for binding to EED and a pIC50 of 8.11±0.09 for inhibiting PRC2 function [1]. The EZH2 mutant DLBCL cell line Karpas422 can be successfully inhibited from proliferating by PROTAC EED degrader-2 (0.01-100 μM; 14 days) [1]. In Karpas422 cells, PROTAC EED degrader-2 (0.1-3 μM; 48 hours) lowers the protein levels of EED, EZH2, and H3K27me3 [1]. In Karpas422 cells, PROTAC EED degrader-2 (1 μM; 1-24 h) stimulates the breakdown of EED, EZH2, and SUZ12 [1]. Reduced proliferation was the outcome of the cell proliferation assay [1] using Karpas422 cells as the cell line. Concentration: 0.01–0.1, 1, 10, 100 μM. Incubation time: 4, 8, 12, and 14 days. GI50 on Day 14 is 0.057 μM.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Karpas422 cells Tested Concentrations: 0.1, 1, and 3 μM Incubation Duration: 48 hrs (hours) Experimental Results: The protein levels of EED, EZH2, H3K27me3 was decreased. Western Blot Analysis[1] Cell Types: Karpas422 cells Tested Concentrations: 1 μM Incubation Duration: 1, 2, 4, 6, 8, 24 hrs (hours) Experimental Results: EED protein levels diminished within 1-2 h of treatment. |
| References |
| Molecular Formula |
C50H58FN11O6S
|
|---|---|
| Molecular Weight |
960.13
|
| Exact Mass |
959.427
|
| CAS # |
2639882-69-0
|
| PubChem CID |
145925664
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.7
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
69
|
| Complexity |
1730
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C(C=CC(=N1)CCC(=O)NCCCCC(=O)N[C@H](C(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=C(N=CS4)C)O)C(C)(C)C)C5=CN=C(N6C5=NN=C6)NCC7=C(C=CC8=C7CCO8)F
|
| InChi Key |
CQSOTYMFUWTIIR-HUSBZTEESA-N
|
| InChi Code |
InChI=1S/C50H58FN11O6S/c1-29-35(38-25-55-49(62-27-57-60-46(38)62)54-24-37-36-19-21-68-41(36)17-16-39(37)51)15-13-33(58-29)14-18-42(64)52-20-7-6-8-43(65)59-45(50(3,4)5)48(67)61-26-34(63)22-40(61)47(66)53-23-31-9-11-32(12-10-31)44-30(2)56-28-69-44/h9-13,15-17,25,27-28,34,40,45,63H,6-8,14,18-24,26H2,1-5H3,(H,52,64)(H,53,66)(H,54,55)(H,59,65)/t34-,40+,45-/m1/s1
|
| Chemical Name |
(2S,4R)-1-[(2S)-2-[5-[3-[5-[5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]-6-methylpyridin-2-yl]propanoylamino]pentanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~80 mg/mL (~83.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (2.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (2.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0415 mL | 5.2076 mL | 10.4153 mL | |
| 5 mM | 0.2083 mL | 1.0415 mL | 2.0831 mL | |
| 10 mM | 0.1042 mL | 0.5208 mL | 1.0415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
